Nighttime Serdexmethylphenidate Dosing for Idiopathic Hypersomnia

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for idiopathic hypersomnia, such as sodium oxybates and CNS stimulants, fail to effectively address excessive daytime sleepiness, sleep inertia, and brain fog without causing adverse effects or requiring complex dosing regimens, and there is a need for a once-daily treatment that does not rely on second-line medications.

Innovation Solution

Administering a nightly dose of serdexmethylphenidate, a conjugate of d-methylphenidate, before bedtime to treat idiopathic hypersomnia, excessive daytime sleepiness, and sleep inertia, with a therapeutically effective amount ranging from 0.1 mg to 500 mg, preferably 240 mg, and administered 0-3 hours before bedtime, either once or twice daily.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional CNS stimulants (modafinil or amphetamine) are prescribed to treat excessive daytime sleepiness in IH patients, then wakefulness is improved, but sleep inertia and brain fog persist

Engineering Contradiction:

ImprovewakefulnessVSAvoidsleep inertia and brain fog

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent changes the timing parameter of methylphenidate administration from daytime to nighttime (0-3 hours before bedtime), which fundamentally alters the drug's effect profile. This parameter change allows the drug to reduce sleep inertia and brain fog upon awakening while maintaining wakefulness during the day, resolving the contradiction between improving wakefulness and eliminating sleep inertia

Inventive Principle:

Principle #35Parameter changes

2Reliability

If sodium oxybates are administered to induce sleep in IH patients, then sleep is improved, but wakefulness and sleep inertia are worsened

Engineering Contradiction:

Improvesleep qualityVSAvoiddifficulty reaching full wakefulness and sleep inertia

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent inverts the conventional approach by administering a stimulant (methylphenidate) at nighttime instead of daytime. This inversion allows the stimulant to counteract sleep inertia during awakening while still permitting natural sleep occurrence, thereby resolving the contradiction between improving sleep quality and reducing sleep inertia

Inventive Principle:

Principle #13The other way round (Inversion)

3Reliability

If conventional treatments are used for IH, then some symptoms are improved, but complex dosing regimens and drug dependence risks increase

Engineering Contradiction:

Improvesymptom treatmentVSAvoiddosing regimen complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent makes the nighttime methylphenidate administration serve multiple functions simultaneously: it treats excessive daytime sleepiness, reduces sleep inertia, and eliminates brain fog. This multi-functionality in a single dosing event resolves the contradiction between effective symptom treatment and dosing regimen complexity

Inventive Principle:

Principle #6Universality (Multi-functionality)

Data Source

PatentUS20250375436A1Serdexmethylphenidate for treatment of idiopathic hypersomnia

Publication Date: 2025.12.11 COMMAVE THERAPEUTICS SA

AI summary

The present technology relates to a method of treating sleep disorders in a patient, the method comprising: administering to the patient before bedtime a composition comprising a therapeutically effective amount of a conjugate of d-methylphenidate having a structure of Formula I or a pharmaceutically acceptable salt thereof, wherein the composition comprising the conjugate of d-methylphenidate is administered about 0-3 hours before the bedtime of the patient.